Trial Profile

Phase I, Randomized, Modified Double-blind, Parallel-group, Active-controlled, Multi-arm, Dose-escalation Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 05 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs MRNA-based flu vaccine-Sanofi Pasteur/Translate Bio (Primary) ; Influenza virus vaccine
Indications Influenza virus infections
Focus Adverse reactions; First in man
Sponsors Sanofi Pasteur

29 Jan 2024 Status changed from active, no longer recruiting to completed.
02 Feb 2023 Planned End Date changed from 4 Jan 2024 to 21 Dec 2023.
02 Feb 2023 Planned primary completion date changed from 4 Jan 2024 to 21 Dec 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com